From: Rofecoxib for dysmenorrhoea: meta-analysis using individual patient data
 |  | Improved with | % improved |  |  | ||
---|---|---|---|---|---|---|---|
Number of trials | Drug and dose (mg) | Active | Placebo | Active | Placebo | Relative risk (95% CI) | NNT (95% CI) |
Six hour ourcomes | |||||||
   1 | Rofecoxib 25 | 66/115 | 45/118 | 57 | 38 | 1.5 (1.1 to 2.0) | 5.0 (3.7 to 7.8) |
   3 | Rofecoxib 50 | 140/226 | 70/225 | 62 | 31 | 2.0 (1.6 to 2.5) | 3.2 (2.4 to 4.5) |
   1 | Ibuprofen 400 | 31/49 | 10/47 | 63 | 21 | 3.0 (1.7 to 5.4) | 2.4 (1.7 to 4.2) |
   2 | Naproxen sodium 550 | 120/181 | 60/178 | 66 | 34 | 2.0 (1.6 to 2.5) | 3.1 (2.4 to 4.4) |
Eight hour ourcomes | |||||||
   1 | Rofecoxib 25 | 70/115 | 44/118 | 61 | 37 | 1.6 (1.2 to 2.2) | 4.2 (2.8 to 9.0) |
   3 | Rofecoxib 50 | 147/226 | 73/225 | 65 | 32 | 2.0 (1.6 to 2.5) | 3.1 (2.4 to 9.0) |
   1 | Ibuprofen 400 | 30/47 | 11/47 | 61 | 21 | 2.6 (1.5 to 4.6) | 2.6 (1.8 to 5.1) |
   2 | Naproxen sodium 550 | 121/181 | 62/178 | 68 | 35 | 2.0 (1.6 to 2.4) | 3.0 (2.3 to 4.3) |
Twelve hour ourcomes | |||||||
   1 | Rofecoxib 25 | 64/115 | 45/118 | 56 | 38 | 1.5 (1.1 to 1.9) | 5.7 (3.3 to 20) |
   3 | Rofecoxib 50 | 135/226 | 74/225 | 60 | 33 | 1.8 (1.5 to 2.3) | 3.7 (2.8 to 5.6) |
   1 | Ibuprofen 400 | 27/49 | 12/47 | 55 | 26 | 2.2 (1.3 to 3.7) | 3.4 (2.1 to 9.2) |
   2 | Naproxen sodium 550 | 111/181 | 62/178 | 61 | 35 | 1.8 (1.4 to 2.2) | 3.8 (2.7 to 6.1) |